Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use

BACKGROUND: Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy. RESULTS: We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Qingyuan, Li, Ying, Fang, Xiaosheng, Zhang, Lingyan, Xue, Chao, Ge, Xueling, Wang, Xin, Jiang, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882323/
https://www.ncbi.nlm.nih.gov/pubmed/31775867
http://dx.doi.org/10.1186/s13062-019-0255-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882323/
https://www.ncbi.nlm.nih.gov/pubmed/31775867
http://dx.doi.org/10.1186/s13062-019-0255-8

Ejemplares similares